Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild-to-moderate COVID-19 Clear all
Withdrawn Phase 1 Interventional

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

NCT05596045
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
ASC10, Placebo
Drug
Lead sponsor
Ascletis Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Anniston, Alabama • Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed No phase listed Observational

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

NCT04681079
View directory record Official record
Conditions
COVID-19
Interventions
albuterol sulfate (MDI), albuterol sulfate (nebulizer)
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients

NCT05941793
View directory record Official record
Conditions
Mild to Moderate COVID-19
Interventions
MBS-COV, Placebo
Drug
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

NCT05616728
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Lomita, California • Los Angeles, California • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Not applicable Interventional

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

NCT04486482
View directory record Official record
Conditions
Mild-to-Moderate COVID-19
Interventions
KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
Cullman, Alabama • Los Angeles, California • Rancho Cucamonga, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

NCT04524663
View directory record Official record
Conditions
Covid19
Interventions
Camostat Mesilate, Placebo, Standard of Care Treatment
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

The Prevent Severe COVID-19 (PRESECO) Study

NCT04600895
View directory record Official record
Conditions
Covid19
Interventions
Favipiravir, Placebo
Drug
Lead sponsor
Appili Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Pelham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

NCT04634409
View directory record Official record
Conditions
COVID-19
Interventions
Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
127
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

NCT04427501
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, LY3832479, LY3853113, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
0 Years and older
Enrollment
3,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Redondo Beach, California • Miami, Florida • Union City, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Withdrawn Phase 2 Interventional

iNOPulse for COVID-19

NCT04398290
View directory record Official record
Conditions
COVID-19, Hypoxemia, Hypoxemic Respiratory Failure
Interventions
Inhaled nitric oxide (iNO), Nitrogen gas, Oxygen gas
Drug
Lead sponsor
Roger Alvarez
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

NCT04523181
View directory record Official record
Conditions
Covid-19
Interventions
Antroquinonol, Placebo
Drug · Other
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19

NCT04662671
View directory record Official record
Conditions
COVID19
Interventions
RD-X19
Device
Lead sponsor
EmitBio Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

NCT04870606
View directory record Official record
Conditions
Efficacy and Safety
Interventions
Proxalutamide (GT0918), Placebo
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Phoenix, Arizona • Long Beach, California • Sandy Springs, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
View directory record Official record
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Tafenoquine in Patients With Mild to Moderate COVID-19

NCT04533347
View directory record Official record
Conditions
COVID 19 Disease
Interventions
Tafenoquine Oral Tablet, Placebo
Drug
Lead sponsor
60 Degrees Pharmaceuticals LLC
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Miami, Florida • Elkhorn, Nebraska • Morgantown, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

NCT05124210
View directory record Official record
Conditions
COVID-19
Interventions
Sotrovimab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
0 Days to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Cullman, Alabama • Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

NCT04486313
View directory record Official record
Conditions
COVID-19
Interventions
Nitazoxanide, Placebo, Vitamin Super B-Complex
Drug · Dietary Supplement
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
12 Years to 120 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Fort Lauderdale, Florida • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

NCT05164120
View directory record Official record
Conditions
COVID-19
Interventions
Belnacasan, Placebo
Drug
Lead sponsor
MedStar Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional

JINZHEN for Treatment of Mild to Moderate COVID-19

NCT05092503
View directory record Official record
Conditions
COVID-19
Interventions
JINZHEN Granules for Oral Solution, Placebo
Drug
Lead sponsor
Lianyungang Kanion Group, Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Canyon Country, California • Hialeah Gardens, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 23, 2026, 4:15 PM EDT